Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients

Purpose: Currently available clinicopathologic prognostic factors are imperfect predictors of clinical course in advanced-stage epithelial ovarian cancer patients. New molecular predictors are needed to identify patients with higher risk of relapse or death from disease. In a retrospective study, we investigated the prognostic impact of activated leukocyte cell adhesion molecule (ALCAM) expression in epithelial ovarian cancer. Experimental Design: We analyzed the effect of cell-anchorage loss on ALCAM cellular localization in vitro and assessed ALCAM expression by immunohistochemistry in a series of 109 well-characterized epithelial ovarian cancer patient samples. Chi-square test, Kaplan-Meier method, and Cox proportional hazard analyses were used to relate ALCAM cellular localization to clinical-pathologic parameters and to overall survival (OS) rate. Results: Loss of epithelial ovarian cancer cell anchorage was associated both in vitro and in vivo with decreased ALCAM membrane expression. In vivo, ALCAM was localized to cell membrane in normal surface ovarian epithelium, whereas in 67% of the epithelial ovarian cancer samples, membrane localization was decreased or even lost, and the molecule was mainly expressed in cytoplasm. Median OS in this group of patients was 58 months, whereas a median OS was not yet reached in patients with ALCAM membrane localization (P = 0.036, hazard ratio [HR] = 2.0, 95% confidence interval [CI] 1.1 to 3.5). In a multivariate Cox regression model including all the available clinicopathologic variables, loss of ALCAM membrane expression was an independent factor of unfavorable prognosis (P = 0.042, HR = 2.15, 95% CI: 1.0 to 4.5). Conclusions: Decreased/lost ALCAM membrane expression is a marker of poorer outcome in epithelial ovarian cancer patients and might help to identify patients who could benefit from more frequent follow-up or alternative therapeutic modalities.

[1]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[2]  Y. van Kooyk,et al.  MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). , 1998, The American journal of pathology.

[3]  J. Baselga,et al.  Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. , 1999, Cancer research.

[4]  J. J. van den Oord,et al.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. , 2000, The American journal of pathology.

[5]  P. Altevogt,et al.  Role of Src Kinases in the ADAM-mediated Release of L1 Adhesion Molecule from Human Tumor Cells* , 2000, The Journal of Biological Chemistry.

[6]  J. Schalken,et al.  Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. , 2000, Biochemical and biophysical research communications.

[7]  G. Swart.  Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. , 2002, European journal of cell biology.

[8]  E. Petricoin,et al.  Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy , 2004, Human Genomics.

[9]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.

[10]  M. Berman.  Future directions in the surgical management of ovarian cancer. , 2003, Gynecologic oncology.

[11]  Marie Joseph,et al.  Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Ozols,et al.  Focus on epithelial ovarian cancer. , 2004, Cancer cell.

[13]  P. Friedl,et al.  The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism , 2004, Journal of Cell Science.

[14]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[15]  J. Sanes,et al.  Axon fasciculation defects and retinal dysplasias in mice lacking the immunoglobulin superfamily adhesion molecule BEN/ALCAM/SC1 , 2004, Molecular and Cellular Neuroscience.

[16]  M Dietel,et al.  ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival , 2004, Journal of Clinical Pathology.

[17]  Luigi Marchionni,et al.  Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 , 2004, Oncogene.

[18]  Troy Stevens,et al.  Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator , 2022 .

[19]  David I. Smith,et al.  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.

[20]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[21]  G. Swart,et al.  Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration? , 2005, Cancer and Metastasis Reviews.

[22]  M. Dimopoulos,et al.  Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[23]  M. West,et al.  Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.

[24]  David L Rimm,et al.  Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[25]  D. Rimm,et al.  Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p 27 Independently Predict for Survival in Epithelial Ovarian Cancer , 2005 .

[26]  Andrea Bolognesi,et al.  Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody , 2005, Journal of Cell Science.

[27]  Liz Y. Han,et al.  The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer , 2006, Clinical Cancer Research.

[28]  M. Gariboldi,et al.  Molecular predictors of response and outcome in ovarian cancer. , 2006, Critical reviews in oncology/hematology.

[29]  A. Munkarah,et al.  Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. , 2006, Gynecologic oncology.

[30]  W. Weichert,et al.  Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer , 2006, Journal of Clinical Pathology.

[31]  M. Gariboldi,et al.  M‐CAM expression as marker of poor prognosis in epithelial ovarian cancer , 2006, International journal of cancer.

[32]  H. Moch,et al.  Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. , 2006, Gynecologic oncology.

[33]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[34]  S. Canevari,et al.  Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment , 2007, Molecular Cancer Therapeutics.

[35]  S. Canevari,et al.  The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells , 2007, Molecular Cancer Research.